{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T06:47:17Z","timestamp":1790232437353,"version":"4.1.0"},"reference-count":144,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Autoimmunity"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1016\/j.jaut.2016.07.005","type":"journal-article","created":{"date-parts":[[2016,8,6]],"date-time":"2016-08-06T02:17:01Z","timestamp":1470449821000},"page":"6-19","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":102,"special_numbering":"C","title":["Cutting edge issues in autoimmune hepatitis"],"prefix":"10.1016","volume":"75","author":[{"given":"Rodrigo","family":"Liberal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward L.","family":"Krawitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M.","family":"Vierling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael P.","family":"Manns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgina","family":"Mieli-Vergani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Vergani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaut.2016.07.005_bib1","first-page":"113","article-title":"Blutprotein und nahrungseiweiss","volume":"15","author":"Leber","year":"1950","journal-title":"Dtsch. Gesellshaff Z Verdan Stoffwechselkr"},{"key":"10.1016\/j.jaut.2016.07.005_bib2","doi-asserted-by":"crossref","first-page":"3292","DOI":"10.3748\/wjg.14.3292","article-title":"Historical reflections on autoimmune hepatitis","volume":"14","author":"Mackay","year":"2008","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.jaut.2016.07.005_bib3","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/S0140-6736(56)91483-0","article-title":"Lupoid hepatitis","volume":"271","author":"Mackay","year":"1956","journal-title":"Lancet"},{"key":"10.1016\/j.jaut.2016.07.005_bib4","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1093\/oxfordjournals.qjmed.a067264","article-title":"Controlled prospective trial of corticosteroid therapy in active chronic hepatitis","volume":"40","author":"Cook","year":"1971","journal-title":"Q.\u00a0J. Med."},{"key":"10.1016\/j.jaut.2016.07.005_bib5","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/S0016-5085(19)33223-8","article-title":"Clinical, biochemical, and histological remission of severe chronic active liver disease: a controlled study of treatments and early prognosis","volume":"63","author":"Soloway","year":"1972","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jaut.2016.07.005_bib6","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0140-6736(73)92125-9","article-title":"Controlled trial of prednisone and azathioprine in active chronic hepatitis","volume":"1","author":"Murray-Lyon","year":"1973","journal-title":"Lancet"},{"key":"10.1016\/j.jaut.2016.07.005_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaut.2015.11.004","article-title":"Diego and giorgina vergani: the two hearts of translational autoimmunity","volume":"66","author":"Liberal","year":"2016","journal-title":"J.\u00a0Autoimmun."},{"key":"10.1016\/j.jaut.2016.07.005_bib8","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1111\/j.1749-6632.1965.tb19000.x","article-title":"Autoimmune hepatitis","volume":"124","author":"Mackay","year":"1965","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.jaut.2016.07.005_bib9","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1002\/hep.1840180435","article-title":"Meeting report: international autoimmune hepatitis group","volume":"18","author":"Johnson","year":"1993","journal-title":"Hepatology"},{"key":"10.1016\/j.jaut.2016.07.005_bib10","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/S0168-8278(99)80297-9","article-title":"International autoimmune hepatitis group report: review of criteria for diagnosis of autoimmune hepatitis","volume":"31","author":"Alvarez","year":"1999","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.jaut.2016.07.005_bib11","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/hep.22322","article-title":"Simplified criteria for the diagnosis of autoimmune hepatitis","volume":"48","author":"Hennes","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.jaut.2016.07.005_bib12","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.jaut.2012.11.002","article-title":"Autoimmune hepatitis: a comprehensive review","volume":"41","author":"Liberal","year":"2013","journal-title":"J.\u00a0Autoimmun."},{"key":"10.1016\/j.jaut.2016.07.005_bib13","doi-asserted-by":"crossref","first-page":"S100","DOI":"10.1016\/j.jhep.2015.03.005","article-title":"Autoimmune hepatitis\u2013update 2015","volume":"62","author":"Manns","year":"2015","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.jaut.2016.07.005_bib14","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.bpg.2011.09.009","article-title":"Pathogenesis of autoimmune hepatitis","volume":"25","author":"Liberal","year":"2011","journal-title":"Best. Pract. Res. Clin. Gastroenterol."},{"key":"10.1016\/j.jaut.2016.07.005_bib15","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1053\/he.2000.5980","article-title":"Autoimmune hepatitis: the investigational and clinical challenges","volume":"31","author":"Czaja","year":"2000","journal-title":"Hepatology"},{"key":"10.1016\/j.jaut.2016.07.005_bib16","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1002\/hep.23584","article-title":"Diagnosis and management of autoimmune hepatitis","volume":"51","author":"Manns","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jaut.2016.07.005_bib17","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0210-5705(03)70452-X","article-title":"Incidence and prevalence of autoimmune hepatitis in the area of the hospital de Sagunto (Spain)","volume":"27","author":"Primo","year":"2004","journal-title":"Gastroenterol. Hepatol."},{"key":"10.1016\/j.jaut.2016.07.005_bib18","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1111\/j.1440-1746.2010.06384.x","article-title":"Population-based epidemiology study of autoimmune hepatitis: a disease of older women?","volume":"25","author":"Ngu","year":"2010","journal-title":"J.\u00a0Gastroenterol. Hepatol."},{"key":"10.1016\/j.jaut.2016.07.005_bib19","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1111\/j.1572-0241.2002.06019.x","article-title":"Prevalence of autoimmune liver disease in Alaska natives","volume":"97","author":"Hurlburt","year":"2002","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.jaut.2016.07.005_bib20","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1080\/00365529850166284","article-title":"Incidence and prevalence of primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis in a Norwegian population","volume":"33","author":"Boberg","year":"1998","journal-title":"Scand. J. Gastroenterol."},{"key":"10.1016\/j.jaut.2016.07.005_bib21","doi-asserted-by":"crossref","first-page":"119","DOI":"10.7861\/clinmedicine.7-2-119","article-title":"Hepatology outpatient service provision in secondary care: a study of liver disease incidence and resource costs","volume":"7","author":"Whalley","year":"2007","journal-title":"Clin. Med."},{"key":"10.1016\/j.jaut.2016.07.005_bib22","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.jhep.2013.10.020","article-title":"Autoimmune hepatitis in Denmark: incidence, prevalence, prognosis, and causes of death. A nationwide registry-based cohort study","volume":"60","author":"Gronbaek","year":"2014","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.jaut.2016.07.005_bib23","doi-asserted-by":"crossref","first-page":"e1237","DOI":"10.1542\/peds.2015-0578","article-title":"Incidence and characteristics of autoimmune hepatitis","volume":"136","author":"Jimenez-Rivera","year":"2015","journal-title":"Pediatrics"},{"key":"10.1016\/j.jaut.2016.07.005_bib24","article-title":"Incidence and prevalence of autoimmune hepatitis in the Ueda area, Japan","author":"Yoshizawa","year":"2015","journal-title":"Hepatol. Res."},{"key":"10.1016\/j.jaut.2016.07.005_bib25","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1016\/j.jhep.2015.02.025","article-title":"Genetics of liver disease: from pathophysiology to clinical practice","volume":"62","author":"Karlsen","year":"2015","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.jaut.2016.07.005_bib26","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1053\/gast.1997.v112.pm9178696","article-title":"Allelic basis for HLA-encoded susceptibility to type 1 autoimmune hepatitis","volume":"112","author":"Strettell","year":"1997","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jaut.2016.07.005_bib27","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1034\/j.1600-0528.2002.017401.x","article-title":"Genetic susceptibilities for immune expression and liver cell injury in autoimmune hepatitis","volume":"174","author":"Czaja","year":"2000","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.jaut.2016.07.005_bib28","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.autrev.2008.11.005","article-title":"HLA class II association with autoimmune hepatitis in Latin America: a meta-analysis","volume":"8","author":"Duarte-Rey","year":"2009","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.jaut.2016.07.005_bib29","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1053\/j.gastro.2014.04.022","article-title":"Genome-wide association study identifies variants associated with autoimmune hepatitis type-1","volume":"147","author":"de Boer","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jaut.2016.07.005_bib30","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1002\/hep.27983","article-title":"Prediction of short- and long-term outcome in patients with autoimmune hepatitis","volume":"62","author":"Kirstein","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jaut.2016.07.005_bib31","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/gene.2014.82","article-title":"HLA-DRB1*03:01 and HLA-DRB1*04:01 modify the presentation and outcome in autoimmune hepatitis type-1","volume":"16","author":"van Gerven","year":"2015","journal-title":"Genes Immun."},{"key":"10.1016\/j.jaut.2016.07.005_bib32","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s00281-009-0170-7","article-title":"Autoimmune hepatitis","volume":"31","author":"Vergani","year":"2009","journal-title":"Semin. Immunopathol."},{"key":"10.1016\/j.jaut.2016.07.005_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/S0168-8278(02)80564-5","article-title":"Different immunogenetic background in autoimmune hepatitis type 1, type 2 and autoimmune sclerosing cholangitis","volume":"36","author":"Underhill","year":"2002","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.jaut.2016.07.005_bib34","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1111\/j.1572-0241.1999.01229.x","article-title":"Genetic heterogeneity in susceptibility to autoimmune hepatitis types 1 and 2","volume":"94","author":"Bittencourt","year":"1999","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.jaut.2016.07.005_bib35","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.jhep.2006.07.034","article-title":"HLA class II influences humoral autoimmunity in patients with type 2 autoimmune hepatitis","volume":"45","author":"Djilali-Saiah","year":"2006","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.jaut.2016.07.005_bib36","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.autrev.2010.09.024","article-title":"Autoimmune hepatitis, HLA and extended haplotypes","volume":"10","author":"Oliveira","year":"2011","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.jaut.2016.07.005_bib37","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.jaut.2015.07.004","article-title":"The immunogenetics of primary biliary cirrhosis: a comprehensive review","volume":"64","author":"Webb","year":"2015","journal-title":"J.\u00a0Autoimmun."},{"key":"10.1016\/j.jaut.2016.07.005_bib38","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jaut.2015.08.016","article-title":"Using GWAS to identify genetic predisposition in hepatic autoimmunity","volume":"66","author":"Webb","year":"2015","journal-title":"J.\u00a0Autoimmun."},{"key":"10.1016\/j.jaut.2016.07.005_bib39","first-page":"1","article-title":"Contemporary issues and future directions in autoimmune hepatitis","author":"Liberal","year":"2016","journal-title":"Expert Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.jaut.2016.07.005_bib40","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.4049\/jimmunol.170.3.1481","article-title":"Cytochrome P4502D6(193-212): a new immunodominant epitope and target of virus\/self cross-reactivity in liver kidney microsomal autoantibody type 1-positive liver disease","volume":"170","author":"Kerkar","year":"2003","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.jaut.2016.07.005_bib41","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1172\/JCI115443","article-title":"LKM-1 autoantibodies recognize a short linear sequence in P450IID6, a cytochrome P-450 monooxygenase","volume":"88","author":"Manns","year":"1991","journal-title":"J.\u00a0Clin. Invest"},{"key":"10.1016\/j.jaut.2016.07.005_bib42","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1034\/j.1600-0676.2001.021004225.x","article-title":"Molecular mimicry and autoimmune liver disease: virtuous intentions, malign consequences","volume":"21","author":"Bogdanos","year":"2001","journal-title":"Liver"},{"key":"10.1016\/j.jaut.2016.07.005_bib43","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1016\/0016-5085(94)90426-X","article-title":"Primary and secondary liver\/kidney microsomal autoantibody response following infection with hepatitis C virus","volume":"106","author":"Mackie","year":"1994","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jaut.2016.07.005_bib44","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1002\/hep.23588","article-title":"Drug-induced autoimmune hepatitis: clinical characteristics and prognosis","volume":"51","author":"Bjornsson","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jaut.2016.07.005_bib45","first-page":"5471","article-title":"Cryptic epitopes on alpha-fetoprotein induce spontaneous immune responses in hepatocellular carcinoma, liver cirrhosis, and chronic hepatitis patients","volume":"59","author":"Bei","year":"1999","journal-title":"Cancer Res."},{"key":"10.1016\/j.jaut.2016.07.005_bib46","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJM197807062990101","article-title":"Detection of antibodies directed against a liver-specific membrane lipoprotein in patients with acute and chronic active hepatitis","volume":"299","author":"Jensen","year":"1978","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.jaut.2016.07.005_bib47","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/S0168-8278(86)80026-5","article-title":"Serum autoantibodies reacting with the hepatic asialoglycoprotein receptor protein (hepatic lectin) in acute and chronic liver disorders","volume":"3","author":"McFarlane","year":"1986","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.jaut.2016.07.005_bib48","first-page":"16","article-title":"Lymphocyte cytotoxicity to autologous hepatocytes in HBsAg-negative chronic active hepatitis","volume":"38","author":"Vergani","year":"1979","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.jaut.2016.07.005_bib49","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/j.1600-0676.1987.tb00361.x","article-title":"Immunoglobulin on the surface of isolated hepatocytes is associated with antibody-dependent cell-mediated cytotoxicity and liver damage","volume":"7","author":"Vergani","year":"1987","journal-title":"Liver"},{"key":"10.1016\/j.jaut.2016.07.005_bib50","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1016\/S0140-6736(00)02166-8","article-title":"Identification of target antigen for SLA\/LP autoantibodies in autoimmune hepatitis","volume":"355","author":"Wies","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.jaut.2016.07.005_bib51","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1053\/jhep.2002.32092","article-title":"Antibodies to conformational epitopes of soluble liver antigen define a severe form of autoimmune liver disease","volume":"35","author":"Ma","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.jaut.2016.07.005_bib52","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1136\/gut.46.4.553","article-title":"Liver\/kidney microsomal antibody type 1 targets CYP2D6 on hepatocyte plasma membrane","volume":"46","author":"Muratori","year":"2000","journal-title":"Gut"},{"key":"10.1016\/j.jaut.2016.07.005_bib53","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/j.1365-2249.2009.03947.x","article-title":"Periductal interleukin-17 production in association with biliary innate immunity contributes to the pathogenesis of cholangiopathy in primary biliary cirrhosis","volume":"157","author":"Harada","year":"2009","journal-title":"Clin. Exp. Immunol."},{"issue":"Suppl.\u00a02","key":"10.1016\/j.jaut.2016.07.005_bib54","first-page":"A412","article-title":"PWE-281 Different effector T cell responses may account for different patterns of liver injury in childhood autoimmune liver disease","volume":"61","author":"Liberal","year":"2012","journal-title":"Gut"},{"key":"10.1016\/j.jaut.2016.07.005_bib55","doi-asserted-by":"crossref","first-page":"e18909","DOI":"10.1371\/journal.pone.0018909","article-title":"Interleukin-17 contributes to the pathogenesis of autoimmune hepatitis through inducing hepatic interleukin-6 expression","volume":"6","author":"Zhao","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.jaut.2016.07.005_bib56","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.autrev.2014.10.012","article-title":"Regulatory T-cells in autoimmune diseases: challenges, controversies and\u2013yet\u2013unanswered questions","volume":"14","author":"Grant","year":"2015","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.jaut.2016.07.005_bib57","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jhep.2004.03.008","article-title":"Impairment of CD4(+)CD25(+) regulatory T-cells in autoimmune liver disease","volume":"41","author":"Longhi","year":"2004","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.jaut.2016.07.005_bib58","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1002\/hep.22914","article-title":"Vigorous activation of monocytes in juvenile autoimmune liver disease escapes the control of regulatory T-cells","volume":"50","author":"Longhi","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.jaut.2016.07.005_bib59","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.jhep.2012.02.029","article-title":"FOXP3+ regulatory T cells in autoimmune hepatitis are fully functional and not reduced in frequency","volume":"57","author":"Peiseler","year":"2012","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.jaut.2016.07.005_bib60","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1016\/j.jhep.2014.05.034","article-title":"Intrahepatic regulatory T cells in autoimmune hepatitis are associated with treatment response and depleted with current therapies","volume":"61","author":"Taubert","year":"2014","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.jaut.2016.07.005_bib61","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1002\/hep.27884","article-title":"In autoimmune hepatitis type 1 or the autoimmune hepatitis-sclerosing cholangitis variant defective regulatory T-cell responsiveness to IL-2 results in low IL-10 production and impaired suppression","volume":"62","author":"Liberal","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jaut.2016.07.005_bib62","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1002\/hep.26583","article-title":"Dysfunctional CD39(POS) regulatory T cells and aberrant control of T-helper type 17 cells in autoimmune hepatitis","volume":"59","author":"Grant","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jaut.2016.07.005_bib63","first-page":"25","article-title":"CD39 mediated regulation of Th17-cell effector function is impaired in juvenile autoimmune liver disease","volume":"66","author":"Liberal","year":"2016","journal-title":"J.\u00a0Autoimmun."},{"key":"10.1016\/j.jaut.2016.07.005_bib64","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1159\/000282067","article-title":"Mouse models for experimental autoimmune hepatitis: limits and chances","volume":"28","author":"Hardtke-Wolenski","year":"2010","journal-title":"Dig. Dis."},{"key":"10.1016\/j.jaut.2016.07.005_bib65","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1002\/hep.1840110106","article-title":"Meyer zum Buschenfelde KH, Cohen IR. Experimental autoimmune hepatitis: disease induction, time course and T-cell reactivity","volume":"11","author":"Lohse","year":"1990","journal-title":"Hepatology"},{"key":"10.1016\/j.jaut.2016.07.005_bib66","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1002\/hep.21796","article-title":"Differential priming of CD8 and CD4 T-cells in animal models of autoimmune hepatitis and cholangitis","volume":"46","author":"Derkow","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.jaut.2016.07.005_bib67","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1084\/jem.20071859","article-title":"Breaking tolerance to the natural human liver autoantigen cytochrome P450 2D6 by virus infection","volume":"205","author":"Holdener","year":"2008","journal-title":"J.\u00a0Exp. Med."},{"issue":"60","key":"10.1016\/j.jaut.2016.07.005_bib68","article-title":"The CYP2D6 animal model: how to induce autoimmune hepatitis in mice","author":"Hintermann","year":"2012","journal-title":"J.\u00a0Vis. Exp."},{"key":"10.1016\/j.jaut.2016.07.005_bib69","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1002\/hep.27998","article-title":"A\u00a0novel \u201chumanized mouse\u201d model for autoimmune hepatitis and the association of gut microbiota with liver inflammation","volume":"62","author":"Yuksel","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jaut.2016.07.005_bib70","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1002\/hep.20109","article-title":"A\u00a0murine model of type 2 autoimmune hepatitis: xenoimmunization with human antigens","volume":"39","author":"Lapierre","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.jaut.2016.07.005_bib71","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1002\/hep.26023","article-title":"Adoptive transfer of ex\u00a0vivo expanded regulatory T cells in an autoimmune hepatitis murine model restores peripheral tolerance","volume":"57","author":"Lapierre","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.jaut.2016.07.005_bib72","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1053\/j.gastro.2008.06.042","article-title":"Fatal autoimmune hepatitis induced by concurrent loss of naturally arising regulatory T cells and PD-1-mediated signaling","volume":"135","author":"Kido","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jaut.2016.07.005_bib73","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jaut.2016.02.007","article-title":"Non-alcoholic fatty liver disease (NAFLD) potentiates autoimmune hepatitis in the CYP2D6 mouse model","volume":"69","author":"Muller","year":"2016","journal-title":"J.\u00a0Autoimmun."},{"key":"10.1016\/j.jaut.2016.07.005_bib74","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1002\/hep.24080","article-title":"Autoimmune acute liver failure: proposed clinical and histological criteria","volume":"53","author":"Stravitz","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.jaut.2016.07.005_bib75","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/hep.20732","article-title":"Autoimmune hepatitis: effect of symptoms and cirrhosis on natural history and outcome","volume":"42","author":"Feld","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.jaut.2016.07.005_bib76","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jaut.2013.08.004","article-title":"Autoimmune hepatitis: contrasts and comparisons in children and adults \u2013 a comprehensive review","volume":"46","author":"Floreani","year":"2013","journal-title":"J.\u00a0Autoimmun."},{"key":"10.1016\/j.jaut.2016.07.005_bib77","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1056\/NEJMra050408","article-title":"Autoimmune hepatitis","volume":"354","author":"Krawitt","year":"2006","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.jaut.2016.07.005_bib78","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1002\/hep.510250308","article-title":"Autoimmune hepatitis in childhood: a 20-year experience","volume":"25","author":"Gregorio","year":"1997","journal-title":"Hepatology"},{"key":"10.1016\/j.jaut.2016.07.005_bib79","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1002\/hep.22432","article-title":"Evaluation of risk factors in the development of hepatocellular carcinoma in autoimmune hepatitis: implications for follow-up and screening","volume":"48","author":"Yeoman","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.jaut.2016.07.005_bib80","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1016\/j.cgh.2015.08.012","article-title":"Autoimmune hepatitis and overlap syndromes: diagnosis and management","volume":"13","author":"Vierling","year":"2015","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.jaut.2016.07.005_bib81","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.jhep.2004.08.002","article-title":"Liver autoimmune serology: a consensus statement from the committee for autoimmune serology of the international autoimmune hepatitis group","volume":"41","author":"Vergani","year":"2004","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.jaut.2016.07.005_bib82","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.autrev.2013.11.009","article-title":"Diagnostic criteria of autoimmune hepatitis","volume":"13","author":"Liberal","year":"2014","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.jaut.2016.07.005_bib83","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1136\/ard.2009.127100","article-title":"ANA screening: an old test with new recommendations","volume":"69","author":"Meroni","year":"2010","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2016.07.005_bib84","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/S0140-6736(87)92024-1","article-title":"Meyer zum Buschenfelde KH. Characterisation of a new subgroup of autoimmune chronic active hepatitis by autoantibodies against a soluble liver antigen","volume":"1","author":"Manns","year":"1987","journal-title":"Lancet"},{"key":"10.1016\/j.jaut.2016.07.005_bib85","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1016\/S0016-5085(96)70020-3","article-title":"Autoantibodies against glucuronosyltransferases differ between viral hepatitis and autoimmune hepatitis","volume":"111","author":"Strassburg","year":"1996","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jaut.2016.07.005_bib86","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/S0140-6736(94)91966-6","article-title":"Recognition of uridine diphosphate glucuronosyl transferases by LKM-3 antibodies in chronic hepatitis D","volume":"344","author":"Philipp","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.jaut.2016.07.005_bib87","series-title":"Pathology of the Liver","first-page":"415","article-title":"Autoimmune hepatitis","author":"Czaja","year":"2001"},{"key":"10.1016\/j.jaut.2016.07.005_bib88","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1007\/s12016-014-8432-0","article-title":"Emperipolesis mediated by CD8 T cells is a characteristic histopathologic feature of autoimmune hepatitis","volume":"48","author":"Miao","year":"2015","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"10.1016\/j.jaut.2016.07.005_bib89","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1111\/his.12558","article-title":"Assessment of the histopathological key features in autoimmune hepatitis","volume":"66","author":"de Boer","year":"2015","journal-title":"Histopathology"},{"key":"10.1016\/j.jaut.2016.07.005_bib90","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/S0022-3476(86)80880-0","article-title":"Liver disease associated with anti-liver-kidney microsome antibody in children","volume":"108","author":"Maggiore","year":"1986","journal-title":"J.\u00a0Pediatr."},{"issue":"Suppl.\u00a02","key":"10.1016\/j.jaut.2016.07.005_bib91","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1159\/000440747","article-title":"Role of histopathology in autoimmune hepatitis","volume":"33","author":"Tiniakos","year":"2015","journal-title":"Dig. Dis."},{"key":"10.1016\/j.jaut.2016.07.005_bib92","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1097\/MPG.0000000000000593","article-title":"Fulminant hepatic failure of autoimmune aetiology in children","volume":"60","author":"Di Giorgio","year":"2015","journal-title":"J.\u00a0Pediatr. Gastroenterol. Nutr."},{"key":"10.1016\/j.jaut.2016.07.005_bib93","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.jhep.2015.06.030","article-title":"EASL clinical practice guidelines: autoimmune hepatitis","volume":"63","author":"European Association for the Study of the L","year":"2015","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.jaut.2016.07.005_bib94","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1053\/jhep.2002.34944","article-title":"American association for the study of liver D. Diagnosis and treatment of autoimmune hepatitis","volume":"36","author":"Czaja","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.jaut.2016.07.005_bib95","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1002\/hep.23924","article-title":"Application of the 2010 American Association for the study of liver diseases criteria of remission to a cohort of Italian patients with autoimmune hepatitis","volume":"52","author":"Muratori","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jaut.2016.07.005_bib96","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1053\/j.gastro.2010.06.046","article-title":"Budesonide induces remission more effectively than prednisone in a controlled trial of patients with autoimmune hepatitis","volume":"139","author":"Manns","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jaut.2016.07.005_bib97","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/j.jpeds.2013.05.042","article-title":"Budesonide versus prednisone with azathioprine for the treatment of autoimmune hepatitis in children and adolescents","volume":"163","author":"Woynarowski","year":"2013","journal-title":"J.\u00a0Pediatr."},{"key":"10.1016\/j.jaut.2016.07.005_bib98","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1016\/j.jpeds.2013.06.064","article-title":"Budesonide for juvenile autoimmune hepatitis? Not yet","volume":"163","author":"Mieli-Vergani","year":"2013","journal-title":"J.\u00a0Pediatr."},{"key":"10.1016\/j.jaut.2016.07.005_bib99","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1097\/MPG.0b013e3181a1c265","article-title":"Autoimmune hepatitis","volume":"49","author":"Mieli-Vergani","year":"2009","journal-title":"J.\u00a0Pediatr. Gastroenterol. Nutr."},{"key":"10.1016\/j.jaut.2016.07.005_bib100","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1053\/jhep.2003.50266","article-title":"Pharmacokinetics and pharmacodynamic action of budesonide in early- and late-stage primary biliary cirrhosis","volume":"38","author":"Hempfling","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.jaut.2016.07.005_bib101","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.jhep.2010.01.037","article-title":"Treatment options for autoimmune hepatitis: a systematic review of randomized controlled trials","volume":"53","author":"Lamers","year":"2010","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.jaut.2016.07.005_bib102","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.jhep.2012.09.009","article-title":"Relapse is almost universal after withdrawal of immunosuppressive medication in patients with autoimmune hepatitis in remission","volume":"58","author":"van Gerven","year":"2013","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.jaut.2016.07.005_bib103","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1517\/14656566.2011.524206","article-title":"Pharmacological management of autoimmune hepatitis","volume":"12","author":"Vergani","year":"2011","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.jaut.2016.07.005_bib104","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1111\/j.1572-0241.2008.02180.x","article-title":"Mycophenolate mofetil as second line therapy in autoimmune hepatitis?","volume":"103","author":"Hennes","year":"2008","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.jaut.2016.07.005_bib105","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1155\/2010\/891252","article-title":"Mycophenolate mofetil for the treatment of autoimmune hepatitis in patients refractory or intolerant to conventional therapy","volume":"24","author":"Sharzehi","year":"2010","journal-title":"Can. J. Gastroenterol."},{"key":"10.1016\/j.jaut.2016.07.005_bib106","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1053\/gast.1996.v110.pm8536867","article-title":"The successful treatment of autoimmune hepatitis with 6-mercaptopurine after failure with azathioprine","volume":"110","author":"Pratt","year":"1996","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jaut.2016.07.005_bib107","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.cgh.2015.09.037","article-title":"Efficacy of 6-mercaptopurine as second-line treatment for patients with autoimmune hepatitis and azathioprine intolerance","volume":"14","author":"Hubener","year":"2016","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.jaut.2016.07.005_bib108","first-page":"CD010233","article-title":"Azathioprine and 6-mercaptopurine for maintenance of surgically-induced remission in Crohn\u2019s disease","volume":"8","author":"Gordon","year":"2014","journal-title":"Cochrane Database Syst. Rev."},{"issue":"Suppl.\u00a02","key":"10.1016\/j.jaut.2016.07.005_bib109","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1159\/000440752","article-title":"AIH: which alternative for difficult-to-treat patients?","volume":"33","author":"Sebode","year":"2015","journal-title":"Dig. Dis."},{"key":"10.1016\/j.jaut.2016.07.005_bib110","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/j.cgh.2008.04.006","article-title":"A\u00a0single center review of the use of mycophenolate mofetil in the treatment of autoimmune hepatitis","volume":"6","author":"Hlivko","year":"2008","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.jaut.2016.07.005_bib111","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.jhep.2009.02.024","article-title":"Mycophenolate mofetil as rescue treatment for autoimmune liver disease in children: a 5-year follow-up","volume":"51","author":"Aw","year":"2009","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.jaut.2016.07.005_bib112","doi-asserted-by":"crossref","first-page":"3232","DOI":"10.3748\/wjg.v13.i23.3232","article-title":"Low-dose tacrolimus ameliorates liver inflammation and fibrosis in steroid refractory autoimmune hepatitis","volume":"13","author":"Larsen","year":"2007","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.jaut.2016.07.005_bib113","doi-asserted-by":"crossref","first-page":"329","DOI":"10.3109\/00365521.2015.1095351","article-title":"Long-term follow-up of patients with difficult to treat type 1 autoimmune hepatitis on Tacrolimus therapy","volume":"51","author":"Than","year":"2016","journal-title":"Scand. J. Gastroenterol."},{"key":"10.1016\/j.jaut.2016.07.005_bib114","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.jhep.2012.11.010","article-title":"Infliximab as a rescue-treatment in difficult-to-treat autoimmune hepatitis","volume":"58","author":"Weiler-Normann","year":"2013","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.jaut.2016.07.005_bib115","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1159\/000322693","article-title":"A\u00a0case of autoimmune hepatitis treated with rituximab","volume":"4","author":"Barth","year":"2010","journal-title":"Case Rep. Gastroenterol."},{"key":"10.1016\/j.jaut.2016.07.005_bib116","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1016\/j.amjmed.2014.06.016","article-title":"Use of sirolimus in the treatment of refractory autoimmune hepatitis","volume":"127","author":"Chatrath","year":"2014","journal-title":"Am. J. Med."},{"key":"10.1016\/j.jaut.2016.07.005_bib117","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.3109\/00365521.2014.998271","article-title":"Everolimus treatment for patients with autoimmune hepatitis and poor response to standard therapy and drug alternatives in use","volume":"50","author":"Ytting","year":"2015","journal-title":"Scand. J. Gastroenterol."},{"key":"10.1016\/j.jaut.2016.07.005_bib118","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1002\/lt.23704","article-title":"Liver transplantation and autoimmune liver diseases","volume":"19","author":"Liberal","year":"2013","journal-title":"Liver Transpl."},{"key":"10.1016\/j.jaut.2016.07.005_bib119","first-page":"315","article-title":"An analysis of the OPTN\/UNOS liver transplant registry","author":"Futagawa","year":"2004","journal-title":"Clin. Transpl."},{"key":"10.1016\/j.jaut.2016.07.005_bib120","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jaut.2015.08.017","article-title":"\u2019De novo\u2019 and \u2019recurrent\u2019 autoimmune hepatitis after liver transplantation: a comprehensive review","volume":"66","author":"Kerkar","year":"2016","journal-title":"J.\u00a0Autoimmun."},{"key":"10.1016\/j.jaut.2016.07.005_bib121","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1002\/lt.21525","article-title":"Liver transplantation for autoimmune hepatitis and the success of aggressive corticosteroid withdrawal","volume":"14","author":"Campsen","year":"2008","journal-title":"Liver Transpl."},{"key":"10.1016\/j.jaut.2016.07.005_bib122","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1002\/lt.21796","article-title":"Risk factors for recurrence of autoimmune hepatitis after liver transplantation","volume":"15","author":"Montano-Loza","year":"2009","journal-title":"Liver Transpl."},{"key":"10.1016\/j.jaut.2016.07.005_bib123","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/S0140-6736(97)06478-7","article-title":"De-novo autoimmune hepatitis after liver transplantation","volume":"351","author":"Kerkar","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.jaut.2016.07.005_bib124","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1053\/jhep.2002.31167","article-title":"Response to steroids in de novo autoimmune hepatitis after liver transplantation","volume":"35","author":"Salcedo","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.jaut.2016.07.005_bib125","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.jhep.2010.09.002","article-title":"International Autoimmune hepatitis G. Overlap syndromes: the international autoimmune hepatitis group (IAIHG) position statement on a controversial issue","volume":"54","author":"Boberg","year":"2011","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.jaut.2016.07.005_bib126","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1002\/hep.510280203","article-title":"Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy","volume":"28","author":"Chazouilleres","year":"1998","journal-title":"Hepatology"},{"key":"10.1016\/j.jaut.2016.07.005_bib127","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1002\/hep.510280210","article-title":"Frequency and nature of the variant syndromes of autoimmune liver disease","volume":"28","author":"Czaja","year":"1998","journal-title":"Hepatology"},{"key":"10.1016\/j.jaut.2016.07.005_bib128","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.jhep.2009.04.009","article-title":"EASL clinical practice guidelines: management of cholestatic liver diseases","volume":"51","author":"European Association for the Study of the L","year":"2009","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.jaut.2016.07.005_bib129","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.jhep.2005.10.017","article-title":"Long term outcome and response to therapy of primary biliary cirrhosis-autoimmune hepatitis overlap syndrome","volume":"44","author":"Chazouilleres","year":"2006","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.jaut.2016.07.005_bib130","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1111\/j.1572-0241.2005.41841.x","article-title":"Clinical course and outcome of autoimmune hepatitis\/primary sclerosing cholangitis overlap syndrome","volume":"100","author":"Floreani","year":"2005","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.jaut.2016.07.005_bib131","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1053\/jhep.2001.22131","article-title":"Autoimmune hepatitis\/sclerosing cholangitis overlap syndrome in childhood: a 16-year prospective study","volume":"33","author":"Gregorio","year":"2001","journal-title":"Hepatology"},{"key":"10.1016\/j.jaut.2016.07.005_bib132","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1002\/hep.22073","article-title":"Prevalence of sclerosing cholangitis in adults with autoimmune hepatitis: evaluating the role of routine magnetic resonance imaging","volume":"47","author":"Abdalian","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.jaut.2016.07.005_bib133","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/S1542-3565(04)00246-0","article-title":"Fulminant hepatic failure as the initial presentation of acute autoimmune hepatitis","volume":"2","author":"Kessler","year":"2004","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.jaut.2016.07.005_bib134","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1002\/lt.21036","article-title":"Usefulness of corticosteroids for the treatment of severe and fulminant forms of autoimmune hepatitis","volume":"13","author":"Ichai","year":"2007","journal-title":"Liver Transpl."},{"key":"10.1016\/j.jaut.2016.07.005_bib135","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.3748\/wjg.v17.i16.2070","article-title":"Optimizing management in autoimmune hepatitis with liver failure at initial presentation","volume":"17","author":"Potts","year":"2011","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.jaut.2016.07.005_bib136","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1111\/j.1572-0241.2004.30457.x","article-title":"Factors predicting relapse and poor outcome in type I autoimmune hepatitis: role of cirrhosis development, patterns of transaminases during remission and plasma cell activity in the liver biopsy","volume":"99","author":"Verma","year":"2004","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.jaut.2016.07.005_bib137","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/j.jhep.2014.05.021","article-title":"Prognosis of acute severe autoimmune hepatitis (AS-AIH): the role of corticosteroids in modifying outcome","volume":"61","author":"Yeoman","year":"2014","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.jaut.2016.07.005_bib138","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1111\/j.1365-2036.2006.02894.x","article-title":"Clinical characteristics of fulminant-type autoimmune hepatitis: an analysis of eleven cases","volume":"23","author":"Miyake","year":"2006","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.jaut.2016.07.005_bib139","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.jhep.2015.04.016","article-title":"Drug-induced liver injury: interactions between drug properties and host factors","volume":"63","author":"Chen","year":"2015","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.jaut.2016.07.005_bib140","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.jaut.2015.10.006","article-title":"The clinical phenotypes of autoimmune hepatitis: a comprehensive review","volume":"66","author":"Wang","year":"2016","journal-title":"J.\u00a0Autoimmun."},{"key":"10.1016\/j.jaut.2016.07.005_bib141","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1002\/hep.24481","article-title":"The use of liver biopsy evaluation in discrimination of idiopathic autoimmune hepatitis versus drug-induced liver injury","volume":"54","author":"Suzuki","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.jaut.2016.07.005_bib142","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1111\/j.1572-0241.2006.00479.x","article-title":"Pregnancy in autoimmune hepatitis: outcome and risk factors","volume":"101","author":"Schramm","year":"2006","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.jaut.2016.07.005_bib143","doi-asserted-by":"crossref","first-page":"J239","DOI":"10.1016\/j.jaut.2011.12.002","article-title":"Outcomes of pregnancy in women with autoimmune hepatitis","volume":"38","author":"Westbrook","year":"2012","journal-title":"J.\u00a0Autoimmun."},{"key":"10.1016\/j.jaut.2016.07.005_bib144","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.jhep.2010.12.012","article-title":"Autoimmune hepatitis","volume":"55","author":"Lohse","year":"2011","journal-title":"J.\u00a0Hepatol."}],"container-title":["Journal of Autoimmunity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896841116301135?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896841116301135?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T08:15:32Z","timestamp":1760256932000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0896841116301135"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":144,"alternative-id":["S0896841116301135"],"URL":"https:\/\/doi.org\/10.1016\/j.jaut.2016.07.005","relation":{},"ISSN":["0896-8411"],"issn-type":[{"value":"0896-8411","type":"print"}],"subject":[],"published":{"date-parts":[[2016,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cutting edge issues in autoimmune hepatitis","name":"articletitle","label":"Article Title"},{"value":"Journal of Autoimmunity","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaut.2016.07.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}